

2010 23 3 1

.	1
.	2
.	7
.	9
.	10
.	14

2010 7 30



	2009	2010		2010		2010	
	1Q	1Q		2Q	%		%
	660	1,018	54.1	1,860	40.7	3,590	21.2
	254	326	28.4	565	10.1	1,080	3.8
	294	544	84.9	1,150	85.6	2,425	63.4
	175	399	127.4	835	121.3	1,750	80.4
	119	145	22.1	315	29.9	675	31.4
	112	148	31.6	145	23.4	85	76.1
	118	148	25.4	135	29.1	60	82.3
	78	93	18.7	81	36.0	30	85.7

1

2

2010 10

EBITDA	143	280	397	572
1	19.68	23.35	20.39	7.55
ROE	2.4%	2.7%	2.3%	0.9%

	2010	2010	2010
	1Q	2Q	
	340	620	1,193
	31	60	122
	198	383	899
	139	270	652
	59	113	247
	111	177	172
	111	182	177
	68	121	108

2010 10

	2010	2010	2010
	1Q	2Q	
	16	26	34
	82	163	330
	82	163	330
	98	189	364
	98	189	364
	65	126	242

	2010	2010
/USD	91	90
/	13	13

	2009	2010		2009	2010	
	1Q	1Q				
	12	16	4	65	150	85
	25	28	3	110	140	30

	2009 1Q	2010 1Q		%		
	660	1,018	358	54.1	329	29
	61	405	343	558.2	329	14
	9.3	39.8				
	254	326	72	28.4	47	25
	407	692	285	70.2	282	4
	294	544	250	84.9	269	19
	83	162	79	95.8	76	3
	8	35	27	318.6	28	1
	23	27	3	13.6	4	1
	61	175	114	187.7	113	1
	175	399	223	127.4	221	2
	119	145	26	22.1	48	22
	112	148	36	31.6	12	23
	11	11	0		1	1
	5	11	6		1	5
	118	148	30	25.4	13	18
	118	148	30	25.4	13	18
	40	56	15		9	6
	0		0			0
	78	93	15	18.7	3	11

	2009 1Q	2010 1Q	%	2010 1Q
	622	640	2.9	1.59
	226	246	8.7	
	286	266	7.1	
	168	169	0.9	
	119	97	18.2	
	110	128	17.0	1.15
	115	129	11.6	1.15
	75	83	11.3	1.11

18.88 21.01

2010 Q

		*1	*2					
	534	340		15	20	868	150	1,018
	526	329		13		868	150	1,018
	8	11		1	20			
	156	31	16	5	8	200	126	326
	379	308	16	10	13	668	24	692
	255	198	82	4	12	527	17	544
	160	139	82	4	1	383	15	399
	95	59			11	143	2	145
	124	111	98	6	0	141	7	148

*1

*

2009 Q

	517	8	5	520	140	660		
	136	3	3	136	118	254		
	381	6	2	384	22	407		
	276	3	1	278	16	294		
	105	3	1	106	6	112		

	2009 1Q	2010 1Q		%	2010			
					2Q			
	513	526	13	2.5	(963)	986	(1,934)	1,942
	459	464	5	1.2	(875)	881	(1,770)	1,765
	54	62	8	14.1	(88)	105	(164)	177
		329	329		(588)	608	(1,110)	1,150
	7	13	6	90.2	(24)	26	(56)	58

	61	404	343	561.8	(700)	739	(1,330)	1,385
[]	(11.7%)	(46.5%)			(45.6%)		(44.0%)	

	2009 1Q	2010 1Q		%	2010			
					2Q			
	136	109	28	20.3	(200)	205	(385)	390
	52	51	0	0.5		101		204
	39	37	2	4.3		78		160
	37	33	4	11.0	(55)	60	(102)	110
	14	22	8	57.7	(53)	45	(120)	105
	2	18	15	646.7		36		80
	20	16	4	19.7		28		73
	15	14	2	11.9		27		53
	4	11	7	156.1		19		40
	10	11	1	15.7		17		35
	8	11	2	28.8		24		51
	12	11	1	12.1		11		11
	9	9	0	2.0		17		34
	9	9	1	6.4		17		33
	9	8	1	11.9		15		29
	8	7	1	11.0		14		25
	8	7	1	8.2		13		25
	7	7	0	4.1		12		24
	7	6	1	7.6		12		24

	2009 1Q	2010 1Q		%	2010	
					2Q	
'09.3	2	8	6	337.3	13	28
'10.1		4	4		6	15
'10.5		0	0		3	7

	48	52	4	8.2	(69)	81	(132)	136
	3	4	1	52.2	(6)	7	(10)	11
	1	5	4	319.8	(5)	9	(8)	16
	1	0	1	97.0	(5)	7	(9)	11

		146	146		(256)	285	(465)	504
		115	115		(211)	190	(413)	394
[]	23	23		(35)	45	(72)	87
		10	10		(24)	26		48
		22	22		(38)	39		66

	7	12	6	82.4	(22)	23	(50)	52
--	---	----	---	------	------	----	------	----

	2010 1 3	2010 4 6	2010 1 6
	363	315	677
	52	43	96
	287	309	596
	149	163	313
	58	66	124
	80	80	159
	24	38	14

	2010 1 3	2010 4 6	2010 1 6
	161	151	312
	127	81	207
[]	25	24	49
	11	17	28
	25	18	42
	14	24	38
	363	315	677

	2010 3	2010 6	
	6,267	6,248	20
	2,876	3,031	156
	138	129	9
	940	1,013	74
	512	642	130
	652	607	45
	324	317	7
	250	250	
	61	73	12
	2	1	1
	3,392	3,216	176
	741	732	9
	430	434	4
	128	128	0
	103	103	0
	27	15	12
	53	51	2
	1,995	1,910	85
	836	802	34
	1,040	992	48
	119	116	3
	656	575	82
	532	453	78
	24	24	0
	102	98	4
	1	1	0
	6,267	6,248	20

	2010 3	2010 6	
	2,833	2,757	75
	2,650	2,584	66
	169	153	16
	1,658	1,664	6
	86	54	32
	74	36	38
	27	26	1
	157	153	4
	334	288	46
	145	210	65
	183	173	9
	98	98	0
	1	0	0
	84	76	9
	3,435	3,490	56
	3,323	3,380	57
	224	224	
	159	159	
	2,947	3,004	57
	6	6	0
	112	110	1
	79	68	12
		0	0
	32	43	11
	6,267	6,248	20

Diagrammatic annotations: A box on the right has arrows pointing to the values 38 and 65 in the third column. Another box on the right has an arrow pointing to the value 57 in the third column.

	2009				2010
	1Q	2Q	3Q	4Q	1Q
	660	662	715	925	1,018
	254	259	278	332	326
	294	326	307	557	544
	175	202	193	400	399
	119	124	114	157	145
	112	77	131	36	148
	11	3	5	4	11
	5	8	8	20	11
	118	72	128	20	148
				24	
	118	72	128	4	148
	78	48	85	2	93

2010 7 30

	/				
	SMP- 508	repaglinide		Novo Nordisk	2009/9
	MEROPEN	meropenem hydrate	1 3g		:1 2g 2010/5

	/				
	SM- 13496	lurasidone hydrochloride			
	SMP- 508	repaglinide		Novo Nordisk	

	/				
	AS- 3201	raniestat			
	DSP- 8153	amlodipine besilate irbesartan			
	SMP- 986				

	/				
	DSP- 3235				SGLT1
	DSP- 3025				TLR7
	SMP- 028				

2010 5

SMP- 508
SMP- 986

2010 5

	/					
	SM- 13496	lurasidone hydrochloride				2009/12
		eslicarbazepine acetate		BIAL		2009/3

	/				/	
	SM- 13496	lurasidone hydrochloride				
		amubicin hydrochloride				
	HFA Nasal MDI	ciclesonide	()	Nycomed		Nasal Spray
		eslicarbazepine acetate		BIAL		

	/				/	
	SMP- 986					
	HFA	ciclesonide	()	Nycomed		12

	/				/	
	SMP- 028					
	DSP- 7238					DPP
	DSP- 8658					PPAR /
	SEP- 227900					
	SEP- 228432					

2010 5

AG- 7352		2003 10 Sunesis SNS- 595
		2005 6 Celgene Pharmion
AS- 3201		2005 9 /
		2006 5 Chelsea
DSP- 3025		2005 3 AstraZeneca
		2007 7 LUNESTA

2010 5

SMP- 601

Protez Pharmaceuticals

2010 7 30

• Novo Nordisk

•

90

HbA_{1c}

•

•

•

-7

-2

-2A

-1A

Negative Syndrome Scale

PANSS Positive and

•

• BIAL

•

23

1 3

1

4

2

12

1

•

•

•

• 2005 9

•

b

/

▪
▪

II

▪

▪
▪

Na

-3

▪

▪
▪

(SGLT1)

-G

▪

-

▪
▪

Toll-like receptor 7 (TLR7)

▪

2004 AstraZeneca

▪ 2005 3 AstraZeneca

AstraZeneca 4

▪

▪
▪

▪

